Marshall H. Woodworth
Known title: Chief Financial OfficerCIK: 0001492648
Marshall H. Woodworth's purchase track record
Marshall H. Woodworth has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/4/2025 | MTVA | $10K | -2.5% | -12.8% | +14.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| MTVA | ▲ Buy | Grant | 28,000 | $0 | 1/23/2026 | View on chart |
| MTVA | ▼ Sell | Gift | 14,200 | $0 | 8/12/2025 | View on chart |
| MTVA | ▲ Buy | Open Market | 14,200 | $10K | 6/4/2025 | View on chart |
| MTVA | ▼ Sell | Tax Withholding | 3,417 | $5K | 3/1/2025 | View on chart |
| MTVA | ▲ Buy | Grant | 33,496 | $0 | 3/1/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
MTVA appoints Dr. Sarah Browne as Chief Medical Officer
MetaVia announced the appointment of Dr. Sarah Browne, M.D., as its new chief medical officer. Dr. Browne brings extensive clinical development experience, which could support the company's ongoing drug development efforts. The move comes as the stock is trading near its $1.41 support level, a point that has been tested many times.
MTVA appoints Dr. Sarah Browne as Chief Medical Officer. MetaVia announced the appointment of Dr. Sarah Browne, M.D., as its new chief medical officer. Dr. Browne brings extensive clinical development experience, which could support the company's ongoing drug development efforts. The move comes as the stock is trading near its $1.41 support level, a point that has been tested many times.